ARCHIVES

FDA Approves Gleevec For First Line Rx Of CML

This article is from The Cancer Letter archive.

Vol. 26 No. 1 | January 31, 2003

Download PDF Visit The Full Archive

Related Articles

New CEO Brings Managed Care Expertise To Network Of Academic Cancer Centers

January 24, 1997

Vaccine Prevented Cervical Pre-Cancers, Non-Invasive Cancers In Phase III Trial

October 28, 2005

Giaccone Joins Georgetown Lombardi Center

February 22, 2013

Protocols Approved During the Month of June 2002

July 26, 2002

Guidelines Adopted For Pathology Review

February 22, 1980

President’s Cancer Panel annual report finds barriers in translational research stall progress.

July 8, 2005